Best Compounded GLP-1 Providers of 2026, Ranked by Pricing Transparency
The best compounded GLP-1 providers in 2026 — Ondra Health, Trimi, and Eden — are the ones that hold your price flat as your dose increases, charge one all-in monthly price with no separate membership fee, and name their compounding pharmacy publicly. Most large providers fail at least one of these tests. This is an independent audit of leading compounded semaglutide and tirzepatide telehealth platforms, scored on those three criteria, with prices and pharmacy disclosures verified against each provider's public site as of July 2026.
Key takeaways
The best compounded GLP-1 providers hold price flat as your dose increases, charge one all-in monthly price with no separate membership fee, and name their compounding pharmacy publicly.
A "from $99/month" headline almost always reflects a starter dose. On escalating-price providers, the real cost rises each time you titrate up — so compare the maintenance-dose price, not the entry rate.
Compounded GLP-1 medications are not FDA-approved and are not therapeutically equivalent to brand-name products. This is true across every provider. Whether treatment is appropriate for you is a licensed provider's decision.
The short answer
Who ranks well, and why
The best compounded GLP-1 providers in 2026 are the ones that hold your price flat as your dose increases, charge one all-in monthly price with no separate membership fee, and name their compounding pharmacy publicly. Ondra Health, Trimi, and Eden clear all three. Most providers fail at least one: several add a separate membership fee, several raise the price as your dose titrates up, and the majority still do not name their pharmacy.
Compounded semaglutide and tirzepatide contain the same active ingredients as their brand-name counterparts, prepared by state-licensed compounding pharmacies under a valid prescription. Legitimate providers price them between roughly $130 and $360 per month, versus $1,000 or more for brand-name at retail. Because the medication is broadly comparable across reputable providers, the real difference between programs is the pricing structure, not the drug. That is what this audit measures.
The transparency audit
We looked at how leading compounded GLP-1 telehealth providers handle three things a patient can verify before paying. Three patterns held across the group.
Ondra Health 2026 provider audit. Each provider scored against its public pricing pages and dose-disclosure language. Methodology below.
This matters because the number on a homepage is rarely the number you pay in month three. A provider advertising a low starter rate at a 2.5 mg dose may bill two to three times as much once you titrate to a maintenance dose, while a flat-rate provider charges the same at every dose. When you compare providers, compare the maintenance-dose all-in cost — including any membership fee — not the headline entry rate.
The regulatory backdrop is worth knowing. The FDA issued 58 warning letters to compounded GLP-1 telehealth companies in September 2025 and 30 more in March 2026, largely for marketing that claimed compounded semaglutide or tirzepatide is "the same as" or "equivalent to" Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications are not FDA-approved and are not therapeutically equivalent to those branded products. On efficacy, the branded trials are the reference point: the STEP 1 trial (New England Journal of Medicine, 2021) reported 14.9% mean weight loss with FDA-approved 2.4 mg semaglutide over 68 weeks, and SURMOUNT-1 (NEJM, 2022) reported 20.9% with FDA-approved 15 mg tirzepatide over 72 weeks. Those figures apply only to the branded products studied; compounded versions have not been evaluated at that trial scale, and individual results vary.
Compounded GLP-1 providers compared by category
Instead of a single ranking, providers are grouped by the category that fits how people actually shop: cheapest on an annual plan, cheapest month-to-month, whether the pharmacy is named, and whether price stays flat as your dose increases. The most useful number is the effective monthly cost — the advertised medication price plus any separate membership or program fee, at a maintenance dose. Prices are verified against each provider's public site as of July 2026 and change frequently; confirm at checkout.
Cheapest on an annual plan
Trimi ($125 tirz) & Cora ($135 tirz)
Lowest published annual rates. Ondra's flat quarterly plan is competitive once you include that the rate never rises with dose.
Certified, names its pharmacy, and flat-dose — all at once
Ondra Health
LegitScript certification is common; most certified providers still won't name their pharmacy. Ondra is the provider here that pairs certification with a named pharmacy, a named prescriber, and flat-dose pricing.
Cheapest month-to-month
Gimme Care ($160 sema / $199 tirz)
Low no-commitment rate, but does not name its pharmacy.
Watch the effective cost
Mochi & Hims
Advertised med price looks low; a separate membership fee pushes the true monthly cost far higher (see table).
Full comparison, sorted by effective monthly cost at a maintenance dose:
| Provider | Sema / Tirz (advertised) | Effective monthly* | Flat by dose | Pharmacy named | LegitScript |
|---|---|---|---|---|---|
| Ondra Health Names pharmacy + flat + certified | Flat quarterly | One all-in price | Yes | Yes | Certified |
| Trimi | $99 / $125 | $99–$125 | Yes | Yes | Certified |
| Gimme Care | $160 / $199 | $160–$199 | Yes | No | Certified |
| Amble | $225 / ~$300 | $225–$300 | Yes | No | Certified |
| Join Fridays | $150 / $240 annual | $150–$240* | Yes | List | Certified |
| Henry Meds | $129 / $179 start | rises by dose | No | Partial | Certified |
| Ro Body | $145 / $199+ | rises by dose | No | No | Check |
| Mochi Health | $199 med + $79 fee | ~$278 | Varies | No | Certified |
| Hims & Hers | $199 / $329 + fee | ~$348 | No | No | Check |
*Effective monthly = advertised medication price plus any separate membership or program fee, at a maintenance dose. "Check" means verify current status on the provider's own site when you enroll. Pricing and certifications change frequently.
A note on that last column: LegitScript certification is now common among established providers, so on its own it no longer separates one from another. What stays rare is the full combination — certification together with a publicly named pharmacy, a named prescribing practice, and pricing that holds flat as your dose increases. Several certified providers in the table above still decline to name their pharmacy. That pairing, not the badge alone, is the signal worth weighing.
How we scored providers
Three criteria you can verify before paying
We scored each provider on whether the price stays flat as the dose titrates up, whether one monthly price covers everything with no separate membership line, and whether the compounding pharmacy is named publicly. We did not weight brand recognition or ad spend.
Flat dose pricing. GLP-1 treatment is titrated, meaning your dose rises over several months. A provider whose price climbs with each dose step can more than double or triple your monthly cost between month one and maintenance. Flat-rate providers charge the same at every dose.
One all-in price. Some providers advertise a low medication price, then bill a separate "membership," "program," or "care" fee as a second subscription line you cancel separately. The all-in cost is medication plus every recurring fee.
Named compounding pharmacy. A provider willing to name its 503A or 503B pharmacy is a provider you can verify. If a platform won't tell you which pharmacy fills your prescription, you can't confirm sourcing — and that opacity is itself a signal worth weighing.
One more thing to ask about: the form of the active ingredient. The FDA has cautioned that some compounded products have used salt forms of the active ingredient (for example, tirzepatide acetate) rather than the base form used in approved products. A transparent provider can tell you which form its pharmacy compounds. It's a reasonable question to raise before you enroll.
The dose-escalation trap
Ask one question before you enter a card number
The "from $99/month" headline almost always reflects a starter dose. On escalating-price providers, the monthly cost rises each time you titrate up, so the price you enroll at is rarely the price you pay at a therapeutic maintenance dose. The question that cuts through it: does the price change as my dose increases? Flat-rate providers answer no.
A clean four-part check before committing: one monthly price should cover consultation, medication, supplies, and shipping; the price should not change as your dose increases; the compounding pharmacy should be named; and a licensed clinician should review your intake before you're billed.
Walk-away red flags flagged by the FDA and consumer reviewers: any price under about $90 per month, a provider claiming "FDA-approved compounded" medication, overseas shipping, oral tirzepatide sold as equivalent, or no physician oversight at any point in the flow.
Why compounded GLP-1 pricing varies 3–4× for the same molecule
Same active ingredient, very different price
Compounded semaglutide and tirzepatide are the same molecules whichever provider you use, yet monthly prices range from roughly $99 to $360. The gap comes from business model, not the drug. Knowing the five drivers helps you judge whether a price is fair.
Pricing model. Flat-rate providers charge one price at every dose; escalating providers raise it as you titrate up, which is what turns a $99 starter into $299 at maintenance.
Membership fees. Some providers advertise a low medication price, then add a separate monthly membership or program fee, so the effective cost is higher than the headline.
Commitment length. Annual prepay plans are usually the cheapest per month; month-to-month costs more for the flexibility.
Pharmacy and sourcing. Named, accredited 503A or 503B pharmacies carry real quality-assurance costs; the cheapest outliers sometimes reflect undisclosed sourcing.
What's bundled. Consultation, supplies, shipping, and provider messaging may be included or billed separately, which changes the true total.
Tirzepatide side effects: what the trial data shows
The most common effects are gastrointestinal and dose-dependent
In the SURMOUNT-1 trial of FDA-approved tirzepatide, the most common side effects were gastrointestinal, tended to appear during dose increases, and generally eased within about four weeks at a stable dose. These figures come from the branded product studied; compounded versions have not been evaluated at that trial scale, and individual results vary.
| Effect | Reported range across doses | Placebo |
|---|---|---|
| Nausea | about 25–29% | about 10% |
| Diarrhea | about 19–23% | about 7–9% |
| Constipation | about 11–17% | lower |
| Vomiting | rises with dose | low |
On efficacy, SURMOUNT-1 (New England Journal of Medicine, 2022) reported average weight reductions of 16.0%, 21.4%, and 20.9% at the 5 mg, 10 mg, and 15 mg doses of FDA-approved tirzepatide over 72 weeks, versus 2.4% for placebo. Serious events such as pancreatitis and gallbladder problems were uncommon. This is general information, not medical advice; discuss side effects and whether treatment is right for you with a licensed provider.
Regulatory status: is compounded GLP-1 still available in 2026?
Availability depends on FDA shortage and compounding decisions
Compounded GLP-1 access is tied to the FDA's shortage determinations. The agency declared the tirzepatide shortage resolved in December 2024, and in April 2026 proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, with a public comment period open through June 29, 2026. Some large compounders paused production in early 2026. Rules are shifting, so confirm current availability in your state with your provider.
Compounded medications are permitted in defined circumstances, such as when a patient needs a formulation an approved product can't meet. They are not generic versions and are not FDA-approved; unlike approved drugs, they aren't tested by the FDA for safety, effectiveness, or quality before marketing.
How Ondra Health maps to this checklist
For transparency, here is how Ondra answers its own audit: clinical care is provided by board-certified providers through Wasef Health, PC; the pharmacy partners are named publicly and are U.S.-licensed 503A or 503B facilities; the platform is LegitScript-certified and HIPAA-compliant; pricing is flat across all doses on a quarterly plan, with shipping included and billing only after a provider approves treatment; and patients have direct, ongoing access for refills, dose changes, and questions. The medications are compounded and not FDA-approved, and whether treatment is appropriate for you is a licensed provider's decision. Use the same audit on any provider you're considering — including this one.
Frequently asked questions
What is the best compounded GLP-1 provider in 2026?
The best providers hold price flat as your dose increases, charge one all-in monthly price with no separate membership fee, and name their compounding pharmacy publicly. Ondra Health, Trimi, and Eden meet all three criteria. The right choice for you also depends on your state, your target dose, and whether you want brand-name insurance coordination.
What is the cheapest compounded GLP-1 provider?
On headline price, Trimi advertises compounded semaglutide from $99/month and tirzepatide from $125/month on annual plans, among the lowest published rates. But the cheapest entry rate is not always the cheapest at a maintenance dose: providers whose price escalates by dose, or that add a separate membership fee, can cost more over a full course than a flat-rate provider with a higher starting number. Compare the maintenance-dose, all-in monthly cost.
Which compounded GLP-1 providers offer flat pricing across all doses?
Providers that hold price flat as your dose increases include Ondra Health, Trimi, Eden, Gimme Care, and Amble. Escalating-price providers, where the monthly cost rises as you titrate up, include Henry Meds, Ro, and Hims. Always confirm current pricing at checkout, since structures change.
Why do some providers advertise $99/month but charge more later?
The $99 rate typically reflects a starter dose, such as 2.5 mg. GLP-1 treatment involves titrating up over months, and on escalating-price providers the monthly cost rises at each dose step, often reaching $199 to $349 at a maintenance dose. Flat-rate providers charge the same amount at every dose.
Why does it matter if a provider names its pharmacy?
Naming the pharmacy lets you verify that your medication is prepared by a licensed U.S. 503A or 503B facility. If a provider won't disclose which pharmacy fills your prescription, you can't verify sourcing, which is a meaningful transparency gap.
Is a lower monthly price always better?
Not necessarily. A low headline price can hide a rising cost as your dose increases, a separate membership fee, cancellation charges, or billing before a provider approves treatment. Compare the full, stable, maintenance-dose cost and what's included — not just the advertised number.
Are compounded GLP-1 medications FDA-approved?
No. Compounded semaglutide and tirzepatide are not FDA-approved and are not therapeutically equivalent to brand-name products. This is true across all providers. Whether a compounded option is appropriate for you is a licensed provider's decision.
What are the most common tirzepatide side effects?
In the SURMOUNT-1 trial of FDA-approved tirzepatide, the most common side effects were gastrointestinal: nausea (about 25–29% across doses), diarrhea (about 19–23%), and constipation (about 11–17%). They tended to appear during dose increases and ease within about four weeks at a stable dose. These figures are from the branded product; individual results vary, and you should discuss side effects with a licensed provider.
Is compounded GLP-1 still available in 2026?
Availability depends on the FDA's shortage and compounding decisions. The FDA declared the tirzepatide shortage resolved in December 2024 and, in April 2026, proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, with a public comment period open through June 29, 2026. Access is shifting, so confirm current availability in your state with your provider.
† This article is for informational purposes only and does not constitute medical advice. Ondra Health is a telehealth platform, not a medical provider, and this content does not establish a provider-patient relationship or replace personalized guidance from a licensed professional. Whether any GLP-1 treatment is appropriate for you is a decision made by a licensed provider based on your individual health. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety, effectiveness, or quality before marketing, and are not therapeutically equivalent to FDA-approved branded products. Provider details, pricing, and certifications are current as of publication and subject to change; verify each provider's current status on its own site. Rankings are non-payable and based on public provider data. Individual results vary.